How Synthetic Data is Helping Healthtech Companies Market Safely

# How Synthetic Data is Helping Healthtech Companies Market Safely

The healthtech sector faces a peculiar challenge. To market their innovations effectively, companies need to demonstrate real-world impact with compelling case studies and data-driven proof points. Yet the very nature of healthcare data, with its stringent privacy requirements and sensitive personal information, makes this extraordinarily difficult. Enter synthetic data, a technology that's rapidly transforming how healthtech companies can showcase their solutions without compromising patient privacy.

If you're working in health or social care innovation, you've likely encountered this tension repeatedly. Your product works brilliantly, your clients are delighted, but when it comes to creating marketing materials, you're stuck navigating a maze of GDPR considerations, NHS data governance protocols, and understandably cautious compliance teams. Synthetic data offers a way through this maze, and it's becoming increasingly sophisticated and accessible.

What Actually Is Synthetic Data?

Before we dive into the marketing applications, let's clarify what we mean by synthetic data. It's not simply anonymised real data (though that's useful too). Synthetic data is artificially generated information that maintains the statistical properties and patterns of real datasets without containing any actual patient information.

Think of it like this: if you photographed a crowd and then hired an artist to paint a different crowd with the same demographic mix, clothing styles, and general characteristics, you'd have something analogous to synthetic data. The painted crowd isn't real, but it accurately represents the original's key features.

Modern synthetic data generation uses machine learning algorithms to understand the patterns, correlations, and distributions within real healthcare data, then creates entirely new records that preserve these relationships. The result is data that behaves like the real thing for analytical purposes but contains zero actual patient information. This distinction matters enormously under UK data protection law.

Why Traditional Approaches Fall Short

Many healthtech companies have traditionally relied on heavily anonymised datasets or carefully selected, consent-based case studies. Both approaches have significant limitations.

Anonymisation sounds straightforward but becomes problematic at scale. The ICO and various tribunal rulings have shown that re-identification is often possible, particularly when datasets are combined or when dealing with rare conditions. Even aggregate data can pose risks when the underlying population is small, something particularly relevant in specialist care settings.

Consent-based approaches work for individual case studies but don't scale well. Obtaining proper consent takes time, limits the volume of examples you can share, and often comes with restrictions on how the information can be used. For a healthtech company wanting to demonstrate impact across thousands of patients or multiple care settings, this approach simply isn't practical.

There's also the innovation bottleneck. Product teams need realistic data to test marketing messages, build demonstrations, and create training materials. Waiting for ethics approvals and data sharing agreements for each marketing initiative slows everything down. In a competitive market where speed matters, this delay can be costly.

Real Marketing Applications for Synthetic Data

Free guide: The Ultimate Guide to Marketing Care Technology

Get the full playbook as a free PDF, no fluff.

So how are forward-thinking healthtech companies actually using synthetic data in their marketing? The applications are more varied than you might expect.

**Product demonstrations** are perhaps the most obvious use case. Instead of showing your diabetes management platform with fictional "John Smith, age 45" placeholder data that convinces nobody, you can populate it with synthetic patient records that reflect realistic clinical patterns, comorbidities, and treatment journeys. Your prospects see something that looks and behaves like their own patient population, making the value proposition immediately tangible.

**Case studies and white papers** benefit enormously from synthetic data. You can illustrate the impact of your solution across representative patient cohorts without waiting months for approvals or worrying about inadvertent disclosure. One mental health technology provider we spoke with recently published outcome data for a synthetic cohort of 500 patients, demonstrating their intervention's effectiveness across different demographic groups and severity levels. The insights were genuine; the patients were not.

**Sales enablement materials** become far more powerful with realistic data. Your sales team can share compelling before-and-after scenarios, ROI calculations based on realistic patient volumes, and implementation roadmaps that reference actual clinical workflows. All without carrying the compliance risk of real patient data on their laptops.

Getting the Technical Details Right

While synthetic data offers clear advantages, quality matters immensely. Poor synthetic data can be misleading or fail to convince knowledgeable prospects. Several technical considerations deserve attention.

The generation methodology should preserve important correlations in your data. If your real patient population shows relationships between age, frailty scores, and hospital readmission rates, your synthetic data must maintain these patterns. Simple random generation won't cut it for sophisticated healthcare audiences.

Statistical validation is essential. Reputable synthetic data should come with documentation showing how closely it mirrors the source data's distributions and relationships. Techniques like propensity score matching and distributional tests help verify quality. If you're generating synthetic data in-house, invest in proper validation. If you're procuring it, ask suppliers for their validation methodology.

Privacy guarantees need to be robust. The best synthetic data generation approaches include privacy-preserving techniques that mathematically limit the risk of the synthetic data revealing information about individuals in the source dataset. Differential privacy is increasingly the gold standard here, offering quantifiable privacy guarantees.

Navigating the Regulatory and Ethical Considerations

Using synthetic data for marketing doesn't mean abandoning governance. Transparency matters. Your marketing materials should be clear that you're using synthetic data where relevant. Most healthcare buyers appreciate the privacy-conscious approach once they understand it.

The ICO's guidance on synthetic data acknowledges its potential but emphasises that generation methodology matters for determining whether it constitutes personal data. Well-generated synthetic data that can't be linked back to individuals typically falls outside GDPR's scope, but documentation of your approach is important.

Some organisations choose to have their synthetic data generation processes reviewed by their Information Governance teams or Data Protection Officers before deploying them in marketing. This upfront investment in validation pays dividends in confidence and speed later.

There's also the question of clinical validity. While synthetic data is excellent for demonstrating functionality and general outcomes, be cautious about making specific clinical claims based solely on synthetic datasets. Real-world evidence still matters for regulatory submissions and clinical publications, even if synthetic data serves your marketing needs.

Looking Ahead

Synthetic data technology is advancing rapidly. Generative AI models, the same technology behind tools like ChatGPT, are being adapted for healthcare data generation with impressive results. These approaches can create increasingly realistic and complex synthetic datasets, including longitudinal patient records, imaging data, and even synthetic clinical notes.

For healthtech companies, this technology represents a genuine unlock. The ability to market effectively while maintaining the highest privacy standards isn't just good ethics, it's good business. In a sector where trust is paramount and data breaches make headlines, demonstrating your commitment to privacy through thoughtful use of synthetic data can itself be a differentiator.

The healthtech companies getting ahead today are those building synthetic data capabilities into their marketing operations from the start, not as an afterthought. If you're still wrestling with how to showcase your innovation without compromising privacy, it might be time to explore what synthetic data could do for your marketing efforts.